14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
GLUE vs RGNX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Monte Rosa Therapeutics, Inc. (GLUE) is the stronger overall head-to-head candidate over REGENXBIO Inc. (RGNX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). GLUE carries a Unified Composite Score of 44.2/100 (HOLD) at $9.18 (10.0x Forward P/E, -214.5% operating margin), whereas RGNX carries 45.3/100 (HOLD) at $7.45 (N/M Forward P/E, -120.4% operating margin).
Composite vs. Pillar Nuance: While RGNX currently prints a higher short-term Unified Composite Score (45.3/100 HOLD vs. GLUE 44.2/100 HOLD), GLUE captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-214.5% vs. -120.4% operating margin) and revenue trajectory (+325.8% vs. -69.2% YoY).
Technical & Structure Timing Caution: GLUE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3); meanwhile RGNX is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $500.9M market capitalization and -120.4% operating margin.
OpEx & R&D Reinvestment55.9% of Rev ($86M)
90D Engineering Disclosures0 Published
Investor FAQ GLUE vs RGNX Key Questions & Quantitative Answers
As of Nov 16, 2026, Monte Rosa Therapeutics, Inc. (GLUE) is the stronger overall head-to-head candidate over REGENXBIO Inc. (RGNX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). GLUE carries a Unified Composite Score of 44.2/100 (HOLD) at $9.18 (10.0x Forward P/E, -214.5% operating margin), whereas RGNX carries 45.3/100 (HOLD) at $7.45 (N/M Forward P/E, -120.4% operating margin). Composite vs. Pillar Nuance: While RGNX currently prints a higher short-term Unified Composite Score (45.3/100 HOLD vs. GLUE 44.2/100 HOLD), GLUE captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-214.5% vs. -120.4% operating margin) and revenue trajectory (+325.8% vs. -69.2% YoY). Technical & Structure Timing Caution: GLUE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3); meanwhile RGNX is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
GLUE leads the Growth & Scale pillar: GLUE posts +325.8% YoY revenue growth and +0.0% YoY earnings growth on $70M TTM revenue (-92.2% gross margin, -214.5% operating margin), compared with RGNX at -69.2% YoY revenue growth and +0.0% YoY earnings growth on $154M TTM revenue (-64.5% gross margin, -120.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), GLUE cumulative revenue shifted +50.0% while RGNX shifted -22.7%. In operating R&D and SG&A reinvestment, GLUE deploys N/A (0 90-day corporate R&D disclosures) versus 55.9% of Rev ($86M) (0 disclosures) for RGNX.
GLUE screens cheaper on headline valuation multiples. GLUE trades at 10.0x Forward P/E, 10.0x Trailing P/E, N/M PEG, and 11.2x EV/Revenue (unreported FCF margin), whereas RGNX trades at N/M Forward P/E, N/M Trailing P/E, 0.26x PEG, and 3.1x EV/Revenue (-100.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GLUE (-35.3% ROE) versus RGNX (-113.2% ROE) capital efficiency.
In options market volatility and institutional positioning, GLUE carries 100.8% implied volatility (16th %ile, Compressed (<25th %ile)), a 6.27x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.95β · 53% Vol realized risk). By comparison, RGNX carries 349.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.82β · 76% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.